Oncology stewardship practice in the United States: A Hematology/Oncology Pharmacy Association national survey.

Autor:	Banez MT; Department of Pharmaceutical Services, University of California, San Francisco, California, USA., Atienza S; Department of Pharmacy, Advocate Health Midwest, Milwaukee, Wisconsin, USA., Butts A; Department of Pharmacy, UK HealthCare, Lexington, Kentucky, USA., Derba M; Department of Pharmacy, Eastern Maine Medical Center, Bangor, Maine, USA., Dicke K; Department of Pharmacy, OhioHealth, Columbus, Ohio, USA., Haverstick K; Pharmacy and Therapeutics Service Line, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA., Heron BB; National Pharmacy Benefits Management, Hematology/Oncology, Department of Veterans Affairs, Hines, Illinois, USA., Cimino SK; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Loop MS; Department of Health Outcomes Research and Policy, Harrison College of Pharmacy, Auburn University, Auburn, Alabama, USA., Hough S; The US Oncology Network, McKesson Specialty Health, The Woodlands, Texas, USA., Merten JA; Chimeric Medical Communications, LLC, St Ansgar, Iowa, USA., Moore DC; Department of Pharmacy, Atrium Health Levine Cancer Institute, Charlotte, North Carolina, USA., Shah V; Department of Pharmacy, Mayo Clinic, Phoenix, Arizona, USA., Taucher KD; Department of Pharmacy, UCHealth, Aurora, Colorado, USA., Zhang JM; Department of Pharmacy, University of Chicago Medical Center, Chicago, Illinois, USA., Mahmoudjafari Z; University of Kansas Health System, Kansas City, Kansas, USA.
Jazyk:	angličtina
Zdroj:	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Aug 01, pp. 10781552241265280. Date of Electronic Publication: 2024 Aug 01.
DOI:	10.1177/10781552241265280
Abstrakt:	Introduction: The treatment of cancer is associated with high risk for toxicity and high cost. Strategies to enhance the value, quality, and safety of cancer care are often managed independently of one another. Oncology stewardship is a potential framework to unify these efforts and enhance outcomes. This landscape survey establishes baseline information on oncology stewardship in the United States. Methods: The Hematology/Oncology Pharmacy Association (HOPA) distributed a 38-item survey composed of demographic, institutional, clinical decision-making, support staff, metrics, and technology sections to 675 HOPA members between 9 September 2022 and 9 October 2022. Results: Most organizations (78%) have adopted general pharmacy stewardship practices; however, only 31% reported having established a formalized oncology stewardship team. More than 70% of respondents reported implementation of biosimilars, formulary management, and dose rounding as oncology stewardship initiatives in both inpatient and outpatient settings. Frequently cited barriers to oncology stewardship included lack of clinical pharmacist availability (74%), lack of oncology stewardship training (62%), lack of physician/provider buy-in (32%), and lack of cost-saving metrics (33%). Only 6.6% of survey respondents reported their organization had defined "value in oncology." Lack of a formalized stewardship program was most often cited (77%) as the rationale for not defining value. Conclusions: Less than one-third of respondents have established oncology stewardship programs; however, most are providing oncology stewardship practices. This manuscript serves as a call to action for stakeholders to work together to formalize oncology stewardship programs that optimize value, quality, and safety for patients with cancer. Competing Interests: Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu